India's CDMO sector positioned for growth as pharma diversifies from China

Indian contract manufacturers are positioned for substantial growth as global pharmaceutical giants diversify their sourcing strategy away from China, according to reports in the sector. Companies such as Sai Life Sciences are investing heavily in production capacity in anticipation of increased demand from this supply-chain reorientation. The announcement indicated that major pharmaceutical players are already strengthening partnerships with Indian CDMO providers, signaling confidence in the region's manufacturing capabilities and regulatory environment.

While the regulatory approval processes governing pharmaceutical manufacturing mean that the full benefits of this transition will emerge gradually rather than immediately, the supply-chain realignment presents what industry observers describe as a landmark opportunity for India's CDMO sector. This shift reflects broader trends in global pharmaceutical manufacturing, where companies seek to reduce concentration risk and geopolitical exposure by diversifying their vendor base across multiple regions. India's established pharmaceutical infrastructure, skilled workforce, and regulatory framework position it as a natural alternative to China for contract manufacturing services. For investors and market participants, this rebalancing could drive sustained capital investment in Indian pharma manufacturing, support employment growth in the sector, and enhance India's strategic importance in global healthcare supply chains over the medium to long term.

Source: Markets-Economic Times